Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5104 - PSA Doubling Time (PSADT) and Proximal PSA Predict Metastasis-Free Survival (MFS) in Men with Biochemically Recurrent Prostate Cancer (BRPC) after Radical Prostatectomy (RP): Implications for Patient Counseling and Clinical Trial Design

Date

10 Sep 2017

Session

Poster display session

Presenters

Mark Markowski

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

M. Markowski1, Y. Chen2, Z. Feng3, B. Trock3, J. Cullen4, D. Suzman1, E. Antonarakis5, C. Paller6, M. Han3, A. Partin3, M. Eisenberger7

Author affiliations

  • 1 Oncology, Johns Hopkins University, 21287 - Baltimore/US
  • 2 Surgery, Center for Prostate Disease Research, Rockville/US
  • 3 Urology, Johns Hopkins University, Baltimore/US
  • 4 Surgery, Center for Prostate Disease Center, Rockville/US
  • 5 Oncology, Johns Hopkins University, 21231 - Baltimore/US
  • 6 Department Of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore/US
  • 7 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 21231-1000 - Baltimore/US
More

Resources

Abstract 5104

Background

We previously reported a relationship between PSADT and MFS in BRPC post RP (Pound 1999; Freedland 2007; Antonarakis 2012). In men with PSADT

Methods

In the CPDR/JHU RP database (31,296), 513 men with BCR (>0.2ng/ml) with PSADT

Results

M+ occurred in 218 of 513 patients with BRPC (median follow up 9 years). Risk of M+ increased for PSADT 6.0-7.5, 4.5-6, 3.0-4.5, and ≤3.0 months, adjusted for pT stage and Gleason score. PP ≥ 10 ng/ml significantly increased risk of M+ in pts with PSADT

Conclusions

In men with PSADT

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.